Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. (Nasdaq: ATRC) is a medical device company focused on surgical treatments and technologies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The ATRC news page on Stock Titan aggregates company announcements, clinical milestones, product updates, and financial disclosures that shape the outlook for this Afib and surgical pain management specialist.
Investors and healthcare professionals following AtriCure can use this feed to monitor earnings releases and financial guidance, which the company regularly reports via Form 8-K and press releases. Recent updates have included preliminary quarterly and full-year revenue results, non-GAAP metrics such as adjusted EBITDA and adjusted loss per share, and commentary on revenue growth across open ablation, minimally invasive ablation, pain management, and appendage management product categories in the United States and international markets.
The news stream also highlights product and technology developments. Examples include the launch of the cryoXT ae device for post-operative pain management following amputation, expansion of the cryoICE ae platform, and first-in-human use of a dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA) using the EnCompass ae clamp. These announcements provide insight into AtriCure’s product pipeline and its efforts to enhance surgical ablation efficiency and pain control.
Another key theme in AtriCure’s news is clinical research and trials. Updates on the LeAAPS trial and the BoxX-NoAF trial illustrate the company’s focus on generating evidence for Afib treatment, LAA exclusion, and reduction of new-onset post-operative Afib. In addition, AtriCure frequently announces participation in major healthcare and investor conferences, offering context on how management communicates its strategy and performance to the market.
By reviewing ATRC news on this page, readers can quickly see the latest disclosures on financial performance, regulatory and clinical milestones, and device launches that may influence perceptions of AtriCure’s business and its role in Afib and surgical pain management.
AtriCure (Nasdaq: ATRC) will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026. The company will host an audio webcast to discuss results at 4:30 p.m. Eastern Time the same day. Investors are asked to register online and to join more than 15 minutes before the call. A live webcast and a replay will be available at the company's investor events page.
AtriCure (Nasdaq: ATRC) reported preliminary, unaudited Q4 2025 revenue of $140.5M (+13% YoY; +12% constant currency) and full-year 2025 revenue of $534.5M (+15% YoY; +14% constant currency). Q4 U.S. revenue was $114.3M and international was $26.2M. Management expects full-year 2025 adjusted EBITDA of $57M–$59M and adjusted loss per share of $0.18–$0.21. Cash and investments totaled about $167M at year-end. For 2026 the company projects revenue of $600M–$610M (+12%–14%), positive adjusted EBITDA of $80M–$82M, net income, and continued positive cash flow.
AtriCure (NASDAQ: ATRC) will participate in the J.P. Morgan 44th Annual Healthcare Conference and present on Wednesday, January 14, 2026 at 10:30 a.m. Pacific Standard Time.
Management presentation will be accessible by a live audio webcast via the company’s Investors website. The presentation covers recent corporate developments in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management.
AtriCure (Nasdaq: ATRC) announced first‑in‑human treatments using a novel dual energy platform that combines Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA) with the EnCompass clamp on December 11, 2025. In the first two patients, total procedural ablation time to create a box lesion isolating pulmonary veins and left atrial posterior wall was less than 60 seconds, with each ablation showing acute electrical isolation.
The company says the system can use RFA, PFA, or both, builds on AtriCure’s Isolator Synergy history (> 450,000 patients treated; > 100 publications), and expects to initiate a clinical trial in the coming year. Advanced RFA and PFA are not yet approved in any market.
AtriCure (Nasdaq: ATRC) will participate in the Piper Sandler 37th Annual Healthcare Conference. Management is scheduled for a fireside discussion on Tuesday, December 2, 2025 at 10:00 a.m. ET. Interested parties may access a live audio webcast via the company's Investors website.
The presentation focuses on company developments in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management.
AtriCure (Nasdaq: ATRC) reported Q3 2025 results: revenue $134.3M (+15.8% YoY; +15.1% constant currency), gross profit $101.3M and gross margin 75.5% (up 59 bps). Q3 net loss was $0.3M (basic/diluted loss $0.01), an improvement of $7.6M versus prior year. Adjusted EBITDA $17.8M (up $9.9M YoY). The company generated $30.1M cash in Q3 and reported cash and equivalents of $147.9M at Sept 30, 2025. Management raised full‑year 2025 guidance to $532M–$534M revenue, Adjusted EBITDA of $55M–$57M, and adjusted loss per share of $0.23–$0.26. A conference call was scheduled for Oct 29, 2025 at 4:30 PM ET.
AtriCure (Nasdaq: ATRC) announced the first patient was enrolled and treated in the BoxX-NoAF randomized IDE clinical trial on October 28, 2025. The trial will evaluate the safety and effectiveness of the Isolator Synergy EnCompass clamp combined with the AtriClip Left Atrial Appendage Exclusion System to reduce new-onset or post-operative atrial fibrillation (POAF) in cardiac surgery patients.
BoxX-NoAF is a prospective, multicenter, randomized trial of up to 960 subjects at up to 75 sites worldwide. AtriCure cited prior enrollment completion of the LeAAPS trial in July 2025 and framed BoxX-NoAF as intended to inform practice and potential labeling for concomitant surgical ablation with LAA management.
AtriCure (Nasdaq: ATRC) announced management will participate in two investor fireside discussions in November 2025. Presentations are scheduled at the UBS Global Healthcare Conference on Monday, November 10, 2025 at 2:00 PM ET and the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 8:40 AM ET.
Both sessions will be available via live audio webcast accessible from the company’s Investors website at https://ir.atricure.com. The presentations will cover the company’s developments in atrial fibrillation treatment, left atrial appendage management, and post-operative pain management.
AtriCure (Nasdaq: ATRC) will release its third quarter 2025 financial results on Wednesday, October 29, 2025. The company will host an audio webcast at 4:30 p.m. Eastern Time the same day to discuss results; interested participants are asked to register online and to register more than 15 minutes before the call. A live and replay version of the audio webcast will be available via the company's investor events page at https://ir.atricure.com/events-and-presentations/events.
AtriCure (NASDAQ: ATRC) has launched the cryoXT™ device, a new cryoablation technology designed for post-operative pain management following amputation procedures. The device, recently cleared by the FDA under a 510(k), addresses a significant market need with over 185,000 annual amputations in the U.S., where approximately 60% of patients experience residual limb pain and up to 85% report phantom limb pain.
The cryoXT device builds upon AtriCure's successful cryoICE® platform, which has been used in over 100,000 procedures since November 2018. The technology features a newly designed tip with multi-surface freezing capability to target large diameter exposed peripheral nerves, temporarily blocking post-amputation pain through nerve ablation.
FAQ
What is the current stock price of Atricure (ATRC)?
What is the market cap of Atricure (ATRC)?
